Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495989 | 0.94 | GABRA5 (0.60) | TSHRALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL16496344 | 0.91 | GABRA5 (0.57) | TSHRALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL16496160 | 0.90 | ALDH1A1 (0.60) | TSHRALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL16495574 | 0.88 | TSHR (0.59) | TSHRALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL16495366 | 0.86 | NPC1 (0.59) | TSHRALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL23535583 | 0.83 | TSHR (0.53) | TSHRALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL16495582 | 0.83 | NAMPT (0.53) | TSHRALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL4707395 | 0.83 | LMNA (0.75) | TSHRALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL16495558 | 0.82 | HPGDS (0.53) | TSHRALDH1A1SMN1; SMN2LMNANAMPT | |
| SCHEMBL25064154 | 0.82 | USP2 (0.52) | TSHRALDH1A1SMN1; SMN2LMNANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | TSHR 3631/4885ALDH1A1 172/4885SMN1; SMN2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.